Kidney disease treatment is undergoing a transformation, driven by exciting new research that reveals the protective power of semaglutide in patients with type 2 diabetes. Semaglutide, a medication ...

Focal segmental glomerulosclerosis (FSGS) is a rare form of kidney inflammation (glomerulonephritis) in which the glomeruli become increasingly scarred (sclerotic), leading to progressive loss of ...

SGLT2 inhibitors (gliflozins) were developed as oral antidiabetics. They enhance urinary glucose excretion by inhibiting SGLT-2 (sodium-dependent glucose co-transporter-2) in the renal tubuli. The ...

The drug finerenone has a positive effect on patients with type 1 diabetes and chronic kidney disease. The drug reduces the amount of proteins excreted in the urine of these patients. This reduction ...

A meta-analysis showed that all doses of tirzepatide, a novel twincretin molecule, reduced albuminuria levels without affecting renal function in patients with type 2 diabetes (T2D). There was ...

"This is the first GLP-1 receptor agonists study to show significant reduction in the risk of kidney failure…Our study establishes GLP-1 receptor agonists as an important kidney-protective class of ...

Our kidneys are vital organs, responsible for filtering waste products and excess fluid from our blood, maintaining electrolyte balance, and producing hormones. Protecting their function is paramount ...

The presence of the M1 genetic variant may confer protection in people with high-risk, APOL1-associated kidney disease, who are predominantly of Black African ancestry, with potentially important ...

Washington, DC November 21, 2025 –(PR.com)– Kidney Care Partners (KCP)—the nation’s largest non-profit, non-partisan kidney care coalition representing patients, dialysis professionals, physicians, ...